CoChat
Sign Up
Cited by 170Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

Open access
Johnson, Erik C. B., Bian, Shijia, Haque, Rafi U., Carter, E. Kathleen, Watson, Caroline M., Gordon, Brian A., Ping, Lingyan, Duong, Duc M., Epstein, Michael P., McDade, Eric, Barthélemy, Nicolas R., Karch, Celeste M., Xiong, Chengjie, Cruchaga, Carlos, Perrin, Richard J., Wingo, Aliza P., Wingo, Thomas S., Chhatwal, Jasmeer P., Day, Gregory S., Noble, James M., Berman, Sarah B., Martins, Ralph, Graff-Radford, Neill R., Schofield, Peter R., Ikeuchi, Takeshi, Mori, Hiroshi, Levin, Johannes, Farlow, Martin, Lah, James J., Haass, Christian, Jucker, Mathias, Morris, John C., Benzinger, Tammie L. S., Roberts, Blaine R., Bateman, Randall J., Fagan, Anne M., Seyfried, Nicholas T., Levey, Allan I., the Dominantly Inherited Alzheimer Network, Vöglein, Jonathan, Allegri, Ricardo, Mendez, Patricio Chrem, Surace, Ezequiel, Berman, Sarah B., Ikonomovic, Snezana, Nadkarni, Neelesh, Lopera, Francisco, Ramirez, Laura, Aguillon, David, Leon, Yudy, Ramos, Claudia, Alzate, Diana, Baena, Ana, Londono, Natalia, Moreno, Sonia, Laske, Christoph, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Preische, Oliver, Hofmann, Anna, Kasuga, Kensaku, Niimi, Yoshiki, Ishii, Kenji, Senda, Michio, Sanchez-Valle, Raquel, Rosa-Neto, Pedro, Fox, Nick, Cash, Dave, Lee, Jae-Hong, Roh, Jee Hoon, Riddle, Meghan, Menard, William, Bodge, Courtney, Surti, Mustafa, Takada, Leonel Tadao, Sanchez-Gonzalez, V. J., Orozco-Barajas, Maribel, Goate, Alison, Renton, Alan, Esposito, Bianca, Marsh, Jacob, Cruchaga, Carlos, Fernandez, Victoria, Jerome, Gina, Herries, Elizabeth, Llibre-Guerra, Jorge, Brooks, William, Bechara, Jacob, Hassenstab, Jason, Franklin, Erin, Chen, Allison, Chen, Charles, Flores, Shaney, Friedrichsen, Nelly, Hantler, Nancy, Hornbeck, Russ, Jarman, Steve, Keefe, Sarah, Koudelis, Deborah, Massoumzadeh, Parinaz, McCullough, Austin, McKay, Nicole, Nicklaus, Joyce, Pulizos, Christine, Wang, Qing, Mishall, Sheetal, Sabaredzovic, Edita, Deng, Emily, Candela, Madison, Smith, Hunter, Hobbs, Diana, Scott, Jalen, Wang, Peter, Xu, Xiong, Li, Yan, Gremminger, Emily, Ma, Yinjiao, Bui, Ryan, Lu, Ruijin, Ortiz, Ana Luisa Sosa, Daniels, Alisha, Courtney, Laura, Supnet-Bell, Charlene, Xu, Jinbin, Ringman, John·2023·Nature Medicine
DOI 10.1038/s41591-023-02476-4PMC PMC10427428
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)—are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aβ plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aβ plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aβ and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aβ and tau.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02476-4

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Aβ42/40 ratio and SMOC1 level in CSF by EYO in ADAD. a,b, The ratio of CSF Aβ42 to Aβ40 peptide as a measure of Aβ brain deposition (a) in ADAD mutation carriers and noncarriers and (b) the difference between carriers and noncarriers, by EYO. One outlier was removed from a for visualization purposes. c,d, CSF level of SMOC1—an Aβ plaque-associated protein—(c) in mutation carriers and noncarriers and (d) the difference between carriers and noncarriers, by EYO. One outlier was removed from c for visualization purposes. EYO labels outside the range of –10 to 10 in a and c are removed to maintain research participant confidentiality. Periods of significant difference between carriers and noncarriers are highlighted in b and d (red indicates significantly increased levels in carriers, blue indicates significantly decreased levels in carriers). Lines represent the median of the posterior estimates at each EYO point for carriers and noncarriers. Shaded areas represent the 99% credible interval. Aβ42 and Aβ40 measurements were from the Fujirebio Lumipulse assay, whereas the SMOC1 measurement was from SRM-MS. L/H, ratio of endogenous peptide signal (light) to the isotopically labeled standard peptide signal (heavy).
Fig. 1 Aβ42/40 ratio and SMOC1 level in CSF by EYO in ADAD. a,b, The ratio of CSF Aβ42 to Aβ40 peptide as a measure of Aβ brain deposition (a) in ADAD mutation carriers and noncarriers and (b) the difference between carriers and noncarriers, by EYO. One outlier was removed from a for visualization purposes. c,d, CSF level of SMOC1—an Aβ plaque-associated protein—(c) in mutation carriers and noncarriers and (d) the difference between carriers and noncarriers, by EYO. One outlier was removed from c for visualization purposes. EYO labels outside the range of –10 to 10 in a and c are removed to maintain research participant confidentiality. Periods of significant difference between carriers and noncarriers are highlighted in b and d (red indicates significantly increased levels in carriers, blue indicates significantly decreased levels in carriers). Lines represent the median of the posterior estimates at each EYO point for carriers and noncarriers. Shaded areas represent the 99% credible interval. Aβ42 and Aβ40 measurements were from the Fujirebio Lumipulse assay, whereas the SMOC1 measurement was from SRM-MS. L/H, ratio of endogenous peptide signal (light) to the isotopically labeled standard peptide signal (heavy).CC BY · PubMed Central
Fig. 2 Categories of biomarker changes by EYO in ADAD. Differences between ADAD mutation carriers and noncarriers in levels of CSF biomarker proteins, imaging measures and cognitive function were modeled across the disease course by EYO. Heat represents significant differences between mutation carriers and noncarriers, with the color threshold set at the 99% credible interval (red, increased in carriers; blue, decreased in carriers). All CSF proteins were measured by MS except for PGRN, c-sTREM2 and NEFL, which were measured by ELISA as previously described20,38,68. Aβ42/40 ratio was measured by the Fujirebio Lumipulse ELISA assay. Additional biomarker measurements are provided in Extended Data Fig. 1. Biomarker measurements available in DIAN used to benchmark the targeted proteomic measurements are shown in gray italics. CSF proteins were mapped to the corresponding AD brain coexpression module as described in ref. 8. Unmapped proteins were not measured in brain. Targeted proteins are listed by their gene symbols. UniProt accessions for each targeted protein are provided in Supplementary Table 2. ALDOA, fructose-bisphosphate aldolase A; CALM2, calmodulin-2; ENO1, alpha-enolase; ENO2, gamma-enolase; FDG-PET precuneus, FDG-PET precuneus signal; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GDA, guanine deaminase; GDI1, rab GDP dissociation inhibitor alpha; GMFB, glia maturation factor beta; GOT1, aspartate aminotransferase; ITGB2, integrin beta-2; LDHB, l-lactate dehydrogenase B chain; LDHC, l-lactate dehydrogenase C chain; MDH1, malate dehydrogenase, cytoplasmic; MFGE8, lactadherin; NPTXR, neuronal pentraxin receptor; NPTX2, neuronal pentraxin-2; PARK7, parkinson disease protein 7; PEBP1, phosphatidylethanolamine-binding protein 1; PGAM1, phosphoglycerate mutase 1; PKM, pyruvate kinase; PKM2, pyruvate kinase 2; PIB-PET Cortex, PIB-PET total cortex signal; PPIA, peptidyl-prolyl cis–trans isomerase A; SCG2, secretogranin-2; t-Tau, tau peptide 181–190, a marker of total tau levels; THY1, thy1 membrane glycoprotein; TPI1, triosephosphate isomerase; VGF, neurosecretory protein VGF; YWHAB, 14-3-3 protein beta; YWHAG, 14-3-3 protein gamma; YWHAZ, 14-3-3 protein zeta.
Fig. 2 Categories of biomarker changes by EYO in ADAD. Differences between ADAD mutation carriers and noncarriers in levels of CSF biomarker proteins, imaging measures and cognitive function were modeled across the disease course by EYO. Heat represents significant differences between mutation carriers and noncarriers, with the color threshold set at the 99% credible interval (red, increased in carriers; blue, decreased in carriers). All CSF proteins were measured by MS except for PGRN, c-sTREM2 and NEFL, which were measured by ELISA as previously described20,38,68. Aβ42/40 ratio was measured by the Fujirebio Lumipulse ELISA assay. Additional biomarker measurements are provided in Extended Data Fig. 1. Biomarker measurements available in DIAN used to benchmark the targeted proteomic measurements are shown in gray italics. CSF proteins were mapped to the corresponding AD brain coexpression module as described in ref. 8. Unmapped proteins were not measured in brain. Targeted proteins are listed by their gene symbols. UniProt accessions for each targeted protein are provided in Supplementary Table 2. ALDOA, fructose-bisphosphate aldolase A; CALM2, calmodulin-2; ENO1, alpha-enolase; ENO2, gamma-enolase; FDG-PET precuneus, FDG-PET precuneus signal; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GDA, guanine deaminase; GDI1, rab GDP dissociation inhibitor alpha; GMFB, glia maturation factor beta; GOT1, aspartate aminotransferase; ITGB2, integrin beta-2; LDHB, l-lactate dehydrogenase B chain; LDHC, l-lactate dehydrogenase C chain; MDH1, malate dehydrogenase, cytoplasmic; MFGE8, lactadherin; NPTXR, neuronal pentraxin receptor; NPTX2, neuronal pentraxin-2; PARK7, parkinson disease protein 7; PEBP1, phosphatidylethanolamine-binding protein 1; PGAM1, phosphoglycerate mutase 1; PKM, pyruvate kinase; PKM2, pyruvate kinase 2; PIB-PET Cortex, PIB-PET total cortex signal; PPIA, peptidyl-prolyl cis–trans isomerase A; SCG2, secretogranin-2; t-Tau, tau peptide 181–190, a marker of total tau levels; THY1, thy1 membrane glycoprotein; TPI1, triosephosphate isomerase; VGF, neurosecretory protein VGF; YWHAB, 14-3-3 protein beta; YWHAG, 14-3-3 protein gamma; YWHAZ, 14-3-3 protein zeta.CC BY · PubMed Central
Fig. 3 Proposed biomarker cascade in ADAD. The magnitude of change depicted by the y axis is arbitrary, and magnitudes are not comparable across different biomarker categories.
Fig. 3 Proposed biomarker cascade in ADAD. The magnitude of change depicted by the y axis is arbitrary, and magnitudes are not comparable across different biomarker categories.CC BY · PubMed Central
Fig. 4 Discrimination of ADAD mutation carriers from noncarriers. a, The ability of Aβ42/40, pTau181, pTau217, SMOC1 and a composite of 33 proteins (proteome) to discriminate mutation carriers from noncarriers across the disease course was assessed using the AUC (higher values equal better discrimination). Each point indicates classification performance (AUC) for carriers and noncarriers over a 10-year time window centered at that particular time point. b, AUC of the ROC curve for each measure with the 10-year time window centered at EYO −20. c, AUC of the ROC curve for each measure with the 10-year time window centered at EYO −10. Significant differences between the proteome and other measures were determined using a nonparametric permutation procedure as described in Methods. The resulting two-sided P values were not corrected for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant.
Fig. 4 Discrimination of ADAD mutation carriers from noncarriers. a, The ability of Aβ42/40, pTau181, pTau217, SMOC1 and a composite of 33 proteins (proteome) to discriminate mutation carriers from noncarriers across the disease course was assessed using the AUC (higher values equal better discrimination). Each point indicates classification performance (AUC) for carriers and noncarriers over a 10-year time window centered at that particular time point. b, AUC of the ROC curve for each measure with the 10-year time window centered at EYO −20. c, AUC of the ROC curve for each measure with the 10-year time window centered at EYO −10. Significant differences between the proteome and other measures were determined using a nonparametric permutation procedure as described in Methods. The resulting two-sided P values were not corrected for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant.CC BY · PubMed Central
Extended Data Fig. 1 Biomarker Changes by Estimated Year of Disease Onset in ADAD. Data is presented as described in Fig. 2, but includes additional measurements of Aβ and tau species. Biomarker measurements available in DIAN used to benchmark the targeted proteomic measurements are shown in gray italics.
Extended Data Fig. 1 Biomarker Changes by Estimated Year of Disease Onset in ADAD. Data is presented as described in Fig. 2, but includes additional measurements of Aβ and tau species. Biomarker measurements available in DIAN used to benchmark the targeted proteomic measurements are shown in gray italics.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Johnson, E. C. B., Bian, S., Haque, R. U., Carter, E. K., Watson, C. M., Gordon, B. A., Ping, L., Duong, D. M., Epstein, M. P., McDade, E., Barthélemy, N. R., Karch, C. M., Xiong, C., Cruchaga, C., Perrin, R. J., Wingo, A. P., Wingo, T. S., Chhatwal, J. P., Day, G. S., Noble, J. M., Berman, S. B., Martins, R., Graff-Radford, N. R., Schofield, P. R., Ikeuchi, T., Mori, H., Levin, J., Farlow, M., Lah, J. J., Haass, C., Jucker, M., Morris, J. C., Benzinger, T. L. S., Roberts, B. R., Bateman, R. J., Fagan, A. M., Seyfried, N. T., Levey, A. I., the Dominantly Inherited Alzheimer Network, Vöglein, J., Allegri, R., Mendez, P. C., Surace, E., Berman, S. B., Ikonomovic, S., Nadkarni, N., Lopera, F., Ramirez, L., Aguillon, D., Leon, Y., Ramos, C., Alzate, D., Baena, A., Londono, N., Moreno, S., Laske, C., Kuder-Buletta, E., Graber-Sultan, S., Preische, O., Hofmann, A., Kasuga, K., Niimi, Y., Ishii, K., Senda, M., Sanchez-Valle, R., Rosa-Neto, P., Fox, N., Cash, D., Lee, J.-H., Roh, J. H., Riddle, M., Menard, W., Bodge, C., Surti, M., Takada, L. T., Sanchez-Gonzalez, V. J., Orozco-Barajas, M., Goate, A., Renton, A., Esposito, B., Marsh, J., Cruchaga, C., Fernandez, V., Jerome, G., Herries, E., Llibre-Guerra, J., Brooks, W., Bechara, J., Hassenstab, J., Franklin, E., Chen, A., Chen, C., Flores, S., Friedrichsen, N., Hantler, N., Hornbeck, R., Jarman, S., Keefe, S., Koudelis, D., Massoumzadeh, P., McCullough, A., McKay, N., Nicklaus, J., Pulizos, C., Wang, Q., Mishall, S., Sabaredzovic, E., Deng, E., Candela, M., Smith, H., Hobbs, D., Scott, J., Wang, P., Xu, X., Li, Y., Gremminger, E., Ma, Y., Bui, R., Lu, R., Ortiz, A. L. S., Daniels, A., Courtney, L., Supnet-Bell, C., Xu, J., & Ringman, J.
Affiliations
  • Emory University (US)
  • Washington University in St. Louis (US)
  • Brigham and Women's Hospital (US)
  • Mayo Clinic in Florida (US)
  • Columbia University Irving Medical Center (US)
  • Edith Cowan University (AU)
  • UNSW Sydney (AU)
  • Brain Research Institute, Niigata University (JP)
  • Osaka Metropolitan University (JP)
  • Ludwig-Maximilians-Universität München (DE)
  • Indiana University Bloomington (US)
  • German Center for Neurodegenerative Diseases (DE)
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (AR)
  • University of Pittsburgh (US)
  • Universidad de Antioquia (CO)
  • University of Tokyo Hospital (JP)
  • Tokyo Metropolitan Institute of Gerontology (JP)
  • Hospital Clínic de Barcelona (ES)
  • UK Dementia Research Institute (GB)
  • Korea University (KR)
  • Brown University (US)
  • Universidade de São Paulo (BR)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Southern California (US)
Corresponding author
Johnson, Erik C. B.
ORCID
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2023-08
Volume
29
Issue
8
Pages
1979-1988
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-023-02476-4
PMC
PMC10427428
OpenAlex
W4385639069
Cited by
170
References
88
Citations by year
2026: 44 · 2025: 64 · 2024: 55 · 2023: 6
FWCI
30.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, cc-by)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Australasian Journal of Paramedicine (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Alzheimer's Association (SG-20-690363-DIAN)
  • Emory University (U01AG061357)
  • Washington University in St. Louis
  • Fondation Brain Canada
  • Japan Agency for Medical Research and Development (17929884, 22dk0207049h0003)
  • Deutsche Forschungsgemeinschaft (HA1737/16‐1, EXC 2145, Koselleck Project HA1737/16-1, EXC 2145SyNergy, 390857198)
  • Korea Health Industry Development Institute
  • Deutsches Zentrum für Neurodegenerative Erkrankungen
  • National Institutes of Health (1s10od025214-01, 1rf1ag071170-01)
  • Canadian Institutes of Health Research
  • Goizueta Business School, Emory University
  • Instituto de Salud Carlos III
  • National Institute on Aging (R01AG056533, RF1 AG071170, AG 024904, AG066444, UF1AG032438, U01AG061357, P01AG003991, U19AG032438, K08AG068604, P30AG066444, U19AG024904, R01AG072120, R01AG075827, P01AG026276, P30AG066511)
  • National Institute of Neurological Disorders and Stroke (R01NS092865)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
autosomal dominant Alzheimer's disease, cerebrospinal fluid proteomics, natural history of disease, amyloid plaques, neurofibrillary tangles, SMOC1, SPON1, presymptomatic biomarkers, mutation carriers, synaptic proteins, neuroinflammation, disease progression
MeSH terms
Adult, Alzheimer Disease, Female, Humans, Male, Middle Aged, Mutation, Biomarkers, Osteonectin, Age of Onset, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review